Elucidation of glycan structures in tumor antigens using high-density lectin arrays

2023 Fiscal Year Final Research Report

• Project/Area Number: 21H03009
• Research Category: Grant-in-Aid for Scientific Research (B)
• Allocation Type: Single-year Grants
• Section: 一般
• Review Section: Basic Section 55020:Digestive surgery-related
• Research Institution: Showa University
• Principal Investigator: WADA SATOSHI 昭和大学, 大学共同利用機関等の部局等, 教授 (30420102)
• Co-Investigator(Kenkyū-buntansha): 舘野 浩章 国立研究開発法人産業技術総合研究所, 生命工学領域, 研究グループ長 (30450670)
• Project Period (FY): 2021-04-01 – 2024-03-31
• Keywords: CAR-T療法 / 腫瘍特異的抗原 / 糖鎖構造 / レクチン

Outline of Final Research Achievements

Based on the results of immunostaining analysis of PIGR using pancreatic cancer tumor tissue samples (90 cases), expression of PIGR molecules was observed in both normal intestinal cells and tumor cells for 11 pancreatic cancer tumor tissue samples. Using these 11 pancreatic cancer tumor tissue samples, normal intestinal cells and tumor cells were separated using a laser microdissection method. PIGR molecules in the isolated cells were isolated by immunoprecipitation and subjected to lectin array analysis. The analysis revealed differences in lectins recognizing carbohydrate chains on some normal cells and tumor cells. Double immunostaining using antibodies and lectins confirmed the differences in expression between normal cells and tumor cells, and we are now preparing CAR-T cells carrying the identified lectins and analyzing their functions.

Free Research Field

腫瘍免疫

Academic Significance and Societal Importance of the Research Achievements

近年がん治療においてCAR-T療法が注目されている。CAR-T療法はこれまでの治療法を遥かに凌駕するほどの強力な治療効果を有する反面副作用が強く、より高い腫瘍特異性が求められている。我々の研究成果は、糖鎖構造を識別することで、腫瘍細胞と正常細胞とを区別出来る事であり、究極の腫瘍特異的抗原の創出となり学術的意義は大きい。また、これまで臨床で使用されているCAR-T療法が、我々の成果により腫瘍細胞のみを完全に標的にすることができ、より副作用の少ない治療薬の開発に繋がり社会的意義はとても大きいと考えられる。